STOCKHOLM, Oct. 16, 2017 /PRNewswire/ --
SciBase has participated in, exhibited and demonstrated their product Nevisense, for early detection of malignant melanoma at the Fall Clinical Dermatology Conference in Las Vegas. The congress was held between 12th and 15 of October and is one of the largest and important national congresses within dermatology. At the congress Darrel S. Rigel, MD and Clinical Professor of Dermatology at the New York University Medical Center presented Nevisense as one of the top ten most important news stories within skin cancer. Nevisense was also presented in a scientific poster by Dr Ryan Svoboda. The poster illustrated the clinical performance of Nevisense and the EIS-method. The first installation and clinical use of Nevisense with patients in the US will be at Dr Rigel's clinic in New York.
- This is the first time we participate in a congress in the US after our FDA approval and our aim has been to introduce Nevisense and build relationships with US dermatologists. We were pleased to establish many contacts during the congress and these will be valuable as we launch our product and method in the US market. It is also pleasing to be able to announce that we now have the first US clinic ready to soon start using Nevisense, says Simon Grant, CEO SciBase.
Professor Rigel is a well-known Key Opinion Leader within dermatology and especially within skin cancer. During one of his congress presentations he listed Nevisense as one of the top ten most important happenings within skin cancer that dermatologists need to know about.
Dr Rigel has presented over 600 times at different congresses, both medical and political, around the world. He is the architect of the so-called ABCDE criteria for melanoma, which are used to help determine if a lesion is benign or malignant. He is also frequently interviewed as an expert on nationwide television channels such as CNN, ABC, FOX, NBC and CBS and his research and opinions are regularly mentioned in the New York Times, Wall Street Journal and many other nationwide newspapers and magazines. Dr Rigel's clinic in New York will be the first clinical installation of Nevisense and will help SciBase understand how to best incorporate Nevisense into the US clinical environment.
The Fall Clinical Dermatology Conference aims to give practicing dermatologists a thorough update regarding diagnostics and treatments of different disorders related to medical, surgical and cosmetic dermatology, including malignant melanoma. The congress is held annually in Las Vegas and attracts about 700-800 dermatologists.
For further information please visit www.scibase.com or contact:
Simon Grant, CEO
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: